ClinConnect ClinConnect Logo
Search / Trial NCT06175208

Targeting Fear of Cancer Recurrence in Cancer Survivors: Evaluation of Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as Intervention Strategies

Launched by GENERAL HOSPITAL GROENINGE · Dec 8, 2023

Trial Information

Current as of June 27, 2025

Enrolling by invitation

Keywords

Fear Of Cancer Recurrence Emotional Freedom Techniques Mindfulness Meditation Cancer Survivors Psychosocial Cancer Related Symptoms

ClinConnect Summary

Despite our adequate medical care and financial support systems, the mental wellbeing and quality of life after cancer diagnosis and treatment is often poorly addressed in clinical settings. Previous research showed that Fear of Cancer Recurrence (FCR) is one of the most common psychological burdens faced by 39%-97% of cancer survivors. In this phase III randomized multicentre trial, patients will be allocated to either the iEFT group, iMMI group or wait-list control (WLC) group for a study trajectory of 6 weeks. 339 cancer survivors, between 6 months and 5 years since diagnosis, and who ha...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients should have reached a minimum age of 18 years at the time of enrolment
  • Patients should have a histologically confirmed diagnosis of a solid cancer or haematologic malignancy
  • Patients should have completed surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted drug therapy or a combination of these at least 2 months ago and no longer than 5 years ago at the time of enrolment
  • Patients should have an expected life expectancy of at least 5 years
  • Patients are disease-free at the time of enrolment, as defined by the absence of somatic disease activity parameters
  • Patients can be included in a stable phase of their immunotherapy (e.g. adjuvant use of checkpoint inhibitors for melanoma), hormonal therapy (e.g. for breast and prostate cancer), targeted drug therapy (e.g. trastuzumab and pertuzumab for breast cancer; stable dose of PARP inhibitors for ovarian cancer; retuximab for lymphoma), or a combination of these
  • Patients must suffer from high FCR based on the Cancer Worry Scale (cut-off ≥ 14)
  • Patients should be able to adequately communicate in Dutch
  • Patients should present with a sufficient mental and physical functional status (according to investigator's judgment and first baseline assessment) for completing the questionnaires and neuropsychological assessment
  • Patients under current treatment for a depression or anxiety disorder are allowed to enrol provided their depression or anxiety disorder is stable
  • Exclusion Criteria:
  • Patients who received a treatment with palliative intent
  • Patients showing signs of mental deterioration
  • Patients suffering from organic brain syndrome (concussion without neurological symptoms and negative imaging is allowed)
  • Patients who are alcohol or drug dependent
  • Patients with another serious or chronic medical, neurologic or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in either of the intervention programmes or from the measurement of intervention outcomes; a prior diagnosis of a depressive, anxiety or adjustment disorder is allowed
  • Patients who cannot commit to the intervention schedule; obstacles such as surgery or long-term hospitalisation, change of residence or work, ... can have an emotional and practical impact which makes these patients not eligible for participation.
  • Patients who actively practice EFT or mindfulness(based) meditation

About General Hospital Groeninge

General Hospital Groeninge is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a robust infrastructure for conducting research, the hospital collaborates with multidisciplinary teams to explore new therapies and treatment protocols across various medical fields. By prioritizing patient safety and ethical standards, General Hospital Groeninge plays a pivotal role in the development of evidence-based medicine, contributing to the global medical community's understanding of health challenges and therapeutic solutions.

Locations

Bonheiden, , Belgium

Edegem, Antwerp, Belgium

Leuven, Vlaams Brabant, Belgium

Tongeren, , Belgium

Ronse, , Belgium

Hasselt, , Belgium

Jette, , Belgium

Brasschaat, Antwerp, Belgium

Sint Niklaas, , Belgium

Gent, East Flanders, Belgium

Kortrijk, West Flanders, Belgium

Antwerp, , Belgium

Patients applied

0 patients applied

Trial Officials

Philip R Debruyne, MD, PhD

Principal Investigator

Kortrijk Cancer Centre,General Hospital Groeninge

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported